Shares of Novavax, Inc. (NASDAQ:NVAX) have earned an average rating of "Buy" from the eight brokerages that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $170.56.
A number of equities research analysts have issued reports on the stock. HC Wainwright reduced their price objective on shares of Novavax from $290.00 to $207.00 and set a "buy" rating on the stock in a research note on Tuesday, November 17th. Zacks Investment Research upgraded shares of Novavax from a "sell" rating to a "strong-buy" rating and set a $134.00 price objective on the stock in a research note on Tuesday, January 12th. B. Riley reduced their price objective on shares of Novavax from $223.00 to $257.00 in a research note on Thursday, October 22nd. Finally, Jefferies Financial Group assumed coverage on shares of Novavax in a research note on Monday, December 14th. They set a "buy" rating and a $200.00 price objective on the stock.
Shares of NVAX traded up $4.58 during trading hours on Friday, hitting $126.98. The company had a trading volume of 2,598,576 shares, compared to its average volume of 3,221,959. The firm has a market cap of $8.08 billion, a price-to-earnings ratio of -24.33 and a beta of 2.01. The business has a fifty day moving average of $122.84 and a 200-day moving average of $115.69. Novavax has a 12 month low of $6.26 and a 12 month high of $189.40. The company has a quick ratio of 2.81, a current ratio of 2.81 and a debt-to-equity ratio of 3.61.
Novavax (NASDAQ:NVAX) last released its quarterly earnings results on Monday, November 9th. The biopharmaceutical company reported ($3.21) EPS for the quarter, missing analysts' consensus estimates of $2.36 by ($5.57). The business had revenue of $157.00 million for the quarter, compared to the consensus estimate of $230.56 million. Novavax had a negative return on equity of 1,346.17% and a negative net margin of 133.10%. The firm's revenue for the quarter was up 6180.0% compared to the same quarter last year. On average, equities analysts expect that Novavax will post -5.49 EPS for the current fiscal year.
In other news, CMO John Trizzino sold 506 shares of the firm's stock in a transaction that occurred on Thursday, January 7th. The shares were sold at an average price of $124.17, for a total value of $62,830.02. Following the sale, the chief marketing officer now directly owns 5,481 shares in the company, valued at approximately $680,575.77. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 3.30% of the company's stock.
A number of hedge funds and other institutional investors have recently made changes to their positions in NVAX. PNC Financial Services Group Inc. increased its position in Novavax by 222.2% in the 2nd quarter. PNC Financial Services Group Inc. now owns 725 shares of the biopharmaceutical company's stock valued at $61,000 after acquiring an additional 500 shares during the period. Sei Investments Co. acquired a new stake in shares of Novavax during the second quarter worth $1,014,000. Great West Life Assurance Co. Can acquired a new stake in shares of Novavax during the second quarter worth $287,000. AQR Capital Management LLC acquired a new stake in shares of Novavax during the second quarter worth $1,874,000. Finally, Principal Financial Group Inc. acquired a new stake in shares of Novavax during the second quarter worth $1,419,000. Hedge funds and other institutional investors own 49.91% of the company's stock.
Novavax Company Profile
Novavax, Inc, together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate that in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase III clinical trial for treating seasonal influenza in older adults.
Read More: What is Compound Annual Growth Rate (CAGR)?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
15 Energy Stocks Analysts Love the Most
There are more than 450 energy companies traded on public markets. Given the sheer number of pipeline companies, power plant operators, oil and gas production companies, and other energy stocks, it can be hard to identify which energy companies will outperform the market.
Fortunately, Wall Street's brightest minds have already done this for us. Every year, analysts issue approximately 8,000 distinct recommendations for energy companies. Analysts don't always get their "buy" ratings right, but it's worth taking a hard look when several analysts from different brokerages and research firms are giving "strong-buy" and "buy" ratings to the same energy stock.
This slide show lists the 15 energy companies with the highest average analyst recommendations from Wall Street's equities research analysts over the last 12 months.
View the "15 Energy Stocks Analysts Love the Most".